Last modified: January 8, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of small molecules for the treatment of anemia and vascular diesease. The company’s lead compound, AKB-6548, is a HIF-PH inhibitor in Phase I clinical trials for anemia. Akebia also has a platform of novel HPTPbeta inhibitors/Angiopoietin 2 modulators which have dmonstrated preclinical proof of concept in vascular leak, angiogenesis and as anti-metastatic agents. The first product to be developed from this platform, AKB-9778, is in late-stage preclinical development. Akebia is based in Cincinnati, Ohio, and is backed by a national syndicate of leading investors.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Akebia Therapeutics Job Trends | Akebia Therapeutics Jobs |
Loading web traffic statistics. Please wait...
- Biotech Showcase 2010 - Presenting Companies (2 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Akebia Therapeutics has been added to the Ecosystem. |